Our Blog

Mesoblast join with Tasly for China deal

12 Oct 2018 – Regenerative medicine comapny Mesoblast (ASX:MSB) today announced completion of the transaction with Tasly Pharmaceutical Group to establish a strategic partnership in China for Mesoblast’s product candidates for heart failure.


Source: Finance News Network

Share this post